Icon

Dovato - (Eq 50 mg/300 mg; Tablet, Oral)

Dolutegravir Sodium and Lamivudine VIIV Healthcare
Eq 50 mg/300 mg; Tablet, Oral
More Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine
Yes
***** ** ***. ***** ***** * **** ** ** ****** '*** *** *** *********. ** ****** **** *** ***** **** ****** ** *** ****. ******** ****** ** ************ ****** ** *** ****. *** *********** - *** **, ****
Dovato Patent 1 Patent 2 Patent 3
***** **** *** ******* *** ********* (***** ******)
****** **** *** **** ** *** **, **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ *** *** *, **** ******* ********* ******** ******* *** **** (***** ******) *** *** ****
****** ** \ ** *** **, **** ******* ********* ******** ***** ***-**** ***********
  1. *** **, **** : ***** ******** **** ********** ***** **'* **** ** ************* ** ****** ******* (*** *, ****)
  2. *** *, **** : **** ********** ***** * **** ******* ***** ** ****** ******* (*** *, ****)
  3. *** *, **** : **** ********** ******* **** ***** ***** ******* *****.
  4. *** **, **** : ****** ******** **** ********** ***** *** **** ** ******.
  5. *** *, **** : **** ********** **** ****** **** ************ ** ****** **. '*** *** '***.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.